Shares of some biotech companies have gotten hammered lately on concerns by Washington lawmakers about the sky-high cost of some new medications. That’s renewing the debate about why drugs cost so much here in the United States, often much more than in other countries.
Hosts
Top Stories from CNBC- The Senate passed Biden’s $1.9 trillion stimulus bill – here’s what’s next
- Senate passes $1.9 trillion Covid relief bill, House Democrats plan final approval Tuesday
- Unemployment benefits end next week. It may be too late for Congress to stop it, experts say
- Stocks face the crosscurrents of higher interest rates and fiscal stimulus in the week ahead
- How Salesforce became Silicon Valley's best late-stage tech investor
